NCT00368277
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
See it on ClinicalTrials.gov ↗901 people
52.4%
47.6%
472 womenmiddle line = equal numbers429 men
- Phase
- PHASE3
- Paid for by
- Novartis Pharmaceuticals
- Finished
- 2008-02
- Health conditions
- Hypertension
- Who could join
- Anyone
- Ages
- 65 Years – no maximum
- Average age
- mean 72.1 years
- Age 65+
- 100%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Current diagnosis of heart failure (New York Heart Association Class III-IV).”
Study titles and rules are shown in their original English.